SUPPLEMENT

Q4 2025 — Other Financial Disclosures

Q4 2025PDF · 17 pages590 KB
Table 1: Sales by Segment 1
Table 2: Sales by Geographic Area 2
Table 3: Sales of Key Products/Franchises 3 - 7
Table 4: Condensed Consolidated Statement of Earnings - QTD 8
Table 5: Condensed Consolidated Statement of Earnings - YTD 9
Table 6: Non-GAAP Adjusted Operational Sales Growth - QTD 10
Table 7: Non-GAAP Adjusted Operational Sales Growth - YTD 11
Table 8: Non-GAAP Adjusted Net Earnings 12
Table 9: Non-GAAP P&L by Segment Reconciliation 2025 - QTD 13
Table 10: Non-GAAP P&L by Segment Reconciliation 2024 - QTD 14
Table 11: Non-GAAP P&L by Segment Reconciliation 2025 - YTD 15
Table 12: Non-GAAP P&L by Segment Reconciliation 2024 - YTD 16
Fourth Quarter 2025
Other Financial Disclosures
Table of Contents

-- 1 of 17 --

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
Percent Change
2025 2024 Total Operations Currency 2025 2024 Total Operations Currency
Sales to customers by
segment of business
Innovative Medicine
U.S. 9,689	$ 8,977 7.9 % 7.9 - 36,344	$ 33,970 7.0 % 7.0 -
International 6,074 5,355 13.4 7.9 5.5 24,057 22,994 4.6 2.9 1.7
15,763 14,332 10.0 7.9 2.1 60,401 56,964 6.0 5.3 0.7
MedTech
U.S. 4,506 4,227 6.6 6.6 - 17,408 16,332 6.6 6.6 -
International 4,295 3,961 8.5 4.9 3.6 16,384 15,525 5.5 4.1 1.4
8,801 8,188 7.5 5.8 1.7 33,792 31,857 6.1 5.4 0.7
U.S. 14,195 13,204 7.5 7.5 - 53,752 50,302 6.9 6.9 -
International 10,369 9,316 11.3 6.6 4.7 40,441 38,519 5.0 3.4 1.6
Worldwide 24,564	$ 22,520 9.1 % 7.1 2.0 94,193	$ 88,821 6.0 % 5.3 0.7
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
FOURTH QUARTER TWELVE MONTHS
Percent Change

-- 2 of 17 --

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
Percent Change
2025 2024 Total Operations Currency 2025 2024 Total Operations Currency
Sales to customers by
geographic area
U.S. 14,195	$ 13,204 7.5 % 7.5 - 53,752	$ 50,302 6.9 % 6.9 -
Europe 5,598 4,921 13.8 5.2 8.6 21,535 20,212 6.5 2.4 4.1
Western Hemisphere excluding U.S. 1,271 1,135 12.0 11.0 1.0 4,875 4,714 3.4 8.4 (5.0)
Asia-Pacific, Africa 3,500 3,260 7.4 7.2 0.2 14,031 13,593 3.2 3.1 0.1
International 10,369 9,316 11.3 6.6 4.7 40,441 38,519 5.0 3.4 1.6
Worldwide 24,564	$ 22,520 9.1 % 7.1 2.0 94,193	$ 88,821 6.0 % 5.3 0.7
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
FOURTH QUARTER TWELVE MONTHS
Percent Change

-- 3 of 17 --

REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM)
FOURTH QUARTER TWELVE MONTHS
INNOVATIVE MEDICINE SEGMENT (2) 2025 2024 Reported Operational (1) Currency 2025 2024 Reported Operational (1) Currency
ONCOLOGY
US 3,793	$ 3,019 25.6% 25.6% - 13,659	$ 10,854 25.8% 25.8% -
Intl 3,069 2,476 23.9% 17.3% 6.6% 11,721 9,926 18.1% 15.6% 2.5%
WW 6,861 5,497 24.8% 21.9% 2.9% 25,380 20,781 22.1% 20.9% 1.2%
CARVYKTI
US 420 304 38.2% 38.2% - 1,492 869 71.6% 71.6% -
Intl 135 31 * * * 395 94 * * *
WW 555 334 65.8% 63.2% 2.6% 1,887 963 95.9% 94.3% 1.6%
DARZALEX
US 2,332 1,799 29.6% 29.6% - 8,266 6,588 25.5% 25.5% -
Intl 1,571 1,285 22.3% 16.2% 6.1% 6,085 5,082 19.7% 17.5% 2.2%
WW 3,903 3,084 26.6% 24.1% 2.5% 14,351 11,670 23.0% 22.0% 1.0%
ERLEADA
US 405 342 18.6% 18.6% - 1,453 1,282 13.4% 13.4% -
Intl 554 442 25.3% 17.5% 7.8% 2,121 1,717 23.5% 20.1% 3.4%
WW 959 784 22.4% 18.0% 4.4% 3,574 2,999 19.2% 17.2% 2.0%
IMBRUVICA
US 207 250 (17.4)% (17.4)% - 892 1,020 (12.5)% (12.5)% -
Intl 478 481 (0.8)% (7.5)% 6.7% 1,931 2,018 (4.3)% (6.7)% 2.4%
WW 684 731 (6.5)% (10.9)% 4.4% 2,823 3,038 (7.1)% (8.6)% 1.5%
RYBREVANT / LAZCLUZE (3)
US 146 101 45.6% 45.6% - 534 257 * * -
Intl 70 21 * * * 200 70 * * *
WW 216 122 78.0% 76.5% 1.5% 734 327 * * *
TALVEY
US 105 68 53.8% 53.8% - 340 241 40.9% 40.9% -
Intl 44 17 * * * 123 46 * * *
WW 149 85 75.8% 73.1% 2.7% 463 287 61.3% 60.3% 1.0%
TECVAYLI
US 110 108 2.7% 2.7% - 444 418 6.3% 6.3% -
Intl 66 38 72.2% 65.1% 7.1% 226 131 72.8% 70.4% 2.4%
WW 176 146 20.8% 18.9% 1.9% 670 549 22.1% 21.5% 0.6%
ZYTIGA / abiraterone acetate
US 5 9 (41.4)% (41.4)% - 23 34 (33.2)% (33.2)% -
Intl 115 127 (9.9)% (11.1)% 1.2% 480 597 (19.7)% (20.5)% 0.8%
WW 119 135 (11.9)% (13.0)% 1.1% 502 631 (20.4)% (21.2)% 0.8%
OTHER ONCOLOGY
US 61 39 54.8% 54.8% - 214 145 47.5% 47.5% -
Intl 39 36 8.4% 3.0% 5.4% 162 172 (6.0)% (7.8)% 1.8%
WW 100 75 32.9% 30.3% 2.6% 376 317 18.5% 17.5% 1.0%
See footnotes at end of schedule
% Change	% Change

-- 4 of 17 --

REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM)
FOURTH QUARTER TWELVE MONTHS
2025 2024 Reported Operational (1) Currency 2025 2024 Reported Operational (1) Currency
IMMUNOLOGY
US 2,495	$ 2,856 (12.6)% (12.6)% - 9,872	$ 11,355 (13.1)% (13.1)% -
Intl 1,364 1,383 (1.4)% (5.5)% 4.1% 5,856 6,473 (9.5)% (10.2)% 0.7%
WW 3,860 4,238 (8.9)% (10.3)% 1.4% 15,728 17,828 (11.8)% (12.0)% 0.2%
REMICADE
US 248 231 7.1% 7.1% - 1,171 1,009 16.0% 16.0% -
US Exports (4) 11 9 17.1% 17.1% - 74 98 (24.8)% (24.8)% -
Intl 110 117 (5.6)% (7.3)% 1.7% 523 497 5.3% 6.2% (0.9)%
WW 370 359 3.2% 2.6% 0.6% 1,768 1,605 10.2% 10.5% (0.3)%
SIMPONI / SIMPONI ARIA
US 287 262 9.6% 9.6% - 1,193 1,082 10.3% 10.3% -
Intl 345 321 7.4% 3.7% 3.7% 1,475 1,108 33.1% 32.8% 0.3%
WW 632 583 8.4% 6.4% 2.0% 2,668 2,190 21.8% 21.7% 0.1%
STELARA
US 766 1,699 (54.9)% (54.9)% - 3,847 6,720 (42.7)% (42.7)% -
Intl 462 650 (28.8)% (32.3)% 3.5% 2,230 3,641 (38.7)% (39.3)% 0.6%
WW 1,230 2,349 (47.7)% (48.6)% 0.9% 6,078 10,361 (41.3)% (41.5)% 0.2%
TREMFYA
US 1,145 654 75.1% 75.1% - 3,529 2,443 44.5% 44.5% -
Intl 445 295 50.9% 44.0% 6.9% 1,626 1,227 32.5% 30.4% 2.1%
WW 1,589 949 67.6% 65.4% 2.2% 5,155 3,670 40.5% 39.8% 0.7%
OTHER IMMUNOLOGY
US 39 0 * * - 59 3 * * -
Intl 2 0 * * * 2 0 * * *
WW 40 0 * * * 61 3 * * *
NEUROSCIENCE
US 1,439 1,148 25.4% 25.4% - 5,151 4,398 17.1% 17.1% -
Intl 675 628 7.6% 4.3% 3.3% 2,686 2,718 (1.2)% (1.8)% 0.6%
WW 2,115 1,775 19.1% 17.9% 1.2% 7,837 7,115 10.1% 9.9% 0.2%
CAPLYTA (5)
US 249 - * * - 700 - * * -
Intl - - - - - - - - - -
WW 249 - * * - 700 - * * -
CONCERTA / Methylphenidate
US 6 33 (79.6)% (79.6)% - 82 134 (38.6)% (38.6)% -
Intl 126 125 (0.3)% (1.4)% 1.1% 502 507 (1.2)% (0.7)% (0.5)%
WW 132 159 (17.1)% (17.8)% 0.7% 584 641 (9.0)% (8.6)% (0.4)%
INVEGA SUSTENNA / XEPLION /
INVEGA TRINZA / TREVICTA
US 704 796 (11.5)% (11.5)% - 2,725 3,125 (12.8)% (12.8)% -
Intl 281 267 5.2% 1.9% 3.3% 1,085 1,097 (1.1)% (1.8)% 0.7%
WW 986 1,063 (7.3)% (8.2)% 0.9% 3,810 4,222 (9.8)% (9.9)% 0.1%
SPRAVATO
US 438 269 63.0% 63.0% - 1,485 929 59.9% 59.9% -
Intl 64 28 * * * 210 148 41.9% 39.1% 2.8%
WW 503 297 69.0% 67.8% 1.2% 1,696 1,077 57.4% 57.0% 0.4%
OTHER NEUROSCIENCE
US 40 49 (18.3)% (18.3)% - 159 210 (24.5)% (24.5)% -
Intl 205 206 (0.7)% (4.3)% 3.6% 889 965 (7.9)% (8.7)% 0.8%
WW 245 255 (4.1)% (6.9)% 2.8% 1,048 1,175 (10.9)% (11.5)% 0.6%
See footnotes at end of schedule
% Change	% Change

-- 5 of 17 --

REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM)
FOURTH QUARTER TWELVE MONTHS
2025 2024 Reported Operational (1) Currency 2025 2024 Reported Operational (1) Currency
PULMONARY HYPERTENSION
US 865	$ 819 5.7% 5.7% - 3,223	$ 3,143 2.6% 2.6% -
Intl 319 274 16.4% 12.2% 4.2% 1,214 1,140 6.5% 4.9% 1.6%
WW 1,184 1,092 8.4% 7.4% 1.0% 4,437 4,282 3.6% 3.2% 0.4%
OPSUMIT / OPSYNVI
US 458 408 11.9% 11.9% - 1,633 1,557 4.8% 4.8% -
Intl 185 162 14.8% 10.9% 3.9% 692 668 3.7% 2.1% 1.6%
WW 643 570 12.7% 11.6% 1.1% 2,325 2,225 4.5% 4.0% 0.5%
UPTRAVI
US 397 391 1.6% 1.6% - 1,536 1,511 1.7% 1.7% -
Intl 94 75 26.9% 20.8% 6.1% 366 307 19.4% 17.4% 2.0%
WW 491 465 5.7% 4.7% 1.0% 1,902 1,817 4.7% 4.3% 0.4%
OTHER PULMONARY HYPERTENSION
US 10 19 (43.7)% (43.7)% - 54 75 (27.0)% (27.0)% -
Intl 39 38 2.6% 1.2% 1.4% 155 165 (6.2)% (6.8)% 0.6%
WW 49 57 (12.5)% (13.5)% 1.0% 209 240 (12.7)% (13.0)% 0.3%
INFECTIOUS DISEASES
US 303 331 (8.5)% (8.5)% - 1,264 1,354 (6.6)% (6.6)% -
Intl 505 443 13.9% 5.6% 8.3% 1,977 2,042 (3.2)% (6.5)% 3.3%
WW 807 774 4.3% (0.4)% 4.7% 3,241 3,396 (4.6)% (6.5)% 1.9%
EDURANT / rilpivirine
US 5 7 (39.1)% (39.1)% - 26 31 (18.4)% (18.4)% -
Intl 379 315 20.6% 11.1% 9.5% 1,461 1,241 17.7% 13.0% 4.7%
WW 383 322 19.2% 9.9% 9.3% 1,486 1,272 16.9% 12.2% 4.7%
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
US 294 321 (8.4)% (8.4)% - 1,226 1,311 (6.5)% (6.5)% -
Intl 89 86 3.6% (2.9)% 6.5% 353 401 (11.9)% (13.7)% 1.8%
WW 383 407 (5.8)% (7.2)% 1.4% 1,579 1,712 (7.7)% (8.1)% 0.4%
OTHER INFECTIOUS DISEASES
US 4 1 92.9% 92.9% - 12 11 6.6% 6.6% -
Intl 37 43 (14.5)% (18.0)% 3.5% 163 401 (59.3)% (59.5)% 0.2%
WW 40 45 (9.9)% (13.2)% 3.3% 175 412 (57.5)% (57.7)% 0.2%
CARDIOVASCULAR / METABOLISM / OTHER
US 794 805 (1.4)% (1.4)% - 3,175 2,866 10.8% 10.8% -
Intl 142 153 (6.3)% (10.7)% 4.4% 603 696 (13.3)% (13.8)% 0.5%
WW 936 957 (2.2)% (2.9)% 0.7% 3,778 3,562 6.1% 6.0% 0.1%
XARELTO
US 687 676 1.7% 1.7% - 2,633 2,373 11.0% 11.0% -
Intl - - - - - - - - - -
WW 687 676 1.7% 1.7% - 2,633 2,373 11.0% 11.0% -
OTHER
US 107 130 (17.4)% (17.4)% - 542 494 9.8% 9.8% -
Intl 142 153 (6.3)% (10.7)% 4.4% 603 696 (13.3)% (13.8)% 0.5%
WW 249 281 (11.4)% (13.8)% 2.4% 1,145 1,189 (3.7)% (4.0)% 0.3%
TOTAL INNOVATIVE MEDICINE
US 9,689 8,977 7.9% 7.9% - 36,344 33,970 7.0% 7.0% -
Intl 6,074 5,355 13.4% 7.9% 5.5% 24,057 22,994 4.6% 2.9% 1.7%
WW 15,763	$ 14,332 10.0% 7.9% 2.1% 60,401	$ 56,964 6.0% 5.3% 0.7%
See footnotes at end of schedule
% Change	% Change

-- 6 of 17 --

REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM)
FOURTH QUARTER TWELVE MONTHS
MEDTECH SEGMENT (2) 2025 2024 Reported Operational (1) Currency 2025 2024 Reported Operational (1) Currency
CARDIOVASCULAR
US 1,374	$ 1,221 12.5% 12.5% - 5,305	$ 4,513 17.5% 17.5% -
Intl 925 841 10.1% 6.8% 3.3% 3,623 3,194 13.4% 11.9% 1.5%
WW 2,299 2,062 11.5% 10.1% 1.4% 8,928 7,707 15.8% 15.2% 0.6%
ELECTROPHYSIOLOGY
US 746 681 9.5% 9.5% - 2,891 2,738 5.6% 5.6% -
Intl 679 640 6.2% 3.2% 3.0% 2,743 2,529 8.5% 7.3% 1.2%
WW 1,425 1,321 7.9% 6.5% 1.4% 5,634 5,267 7.0% 6.4% 0.6%
ABIOMED
US 358 308 16.5% 16.5% - 1,393 1,213 14.9% 14.9% -
Intl 102 77 33.1% 25.4% 7.7% 358 284 26.4% 22.0% 4.4%
WW 460 384 19.8% 18.3% 1.5% 1,751 1,496 17.1% 16.2% 0.9%
SHOCKWAVE
US 238 202 18.0% 18.0% - 897 442 * * -
Intl 80 56 42.3% 40.7% 1.6% 249 122 * * *
WW 318 258 23.3% 22.9% 0.4% 1,146 564 * * *
OTHER CARDIOVASCULAR
US 31 31 (0.1)% (0.1)% - 124 120 3.1% 3.1% -
Intl 64 68 (6.7)% (8.8)% 2.1% 273 260 4.9% 4.1% 0.8%
WW 95 99 (4.6)% (6.1)% 1.5% 397 380 4.3% 3.8% 0.5%
ORTHOPAEDICS
US 1,520 1,460 4.2% 4.2% - 5,720 5,689 0.5% 0.5% -
Intl 918 856 7.3% 2.3% 5.0% 3,538 3,470 2.0% (0.2)% 2.2%
WW 2,438 2,315 5.3% 3.5% 1.8% 9,258 9,158 1.1% 0.3% 0.8%
HIPS
US 284 272 4.3% 4.3% - 1,080 1,057 2.1% 2.1% -
Intl 154 146 5.5% 0.4% 5.1% 594 581 2.2% 0.1% 2.1%
WW 439 418 4.7% 2.9% 1.8% 1,674 1,638 2.1% 1.4% 0.7%
KNEES
US 251 238 5.1% 5.1% - 924 922 0.2% 0.2% -
Intl 181 160 13.7% 9.2% 4.5% 663 623 6.5% 4.6% 1.9%
WW 432 398 8.6% 6.8% 1.8% 1,587 1,545 2.7% 2.0% 0.7%
TRAUMA
US 543 514 5.6% 5.6% - 2,058 2,013 2.2% 2.2% -
Intl 270 250 7.9% 2.7% 5.2% 1,088 1,036 5.0% 2.7% 2.3%
WW 813 764 6.4% 4.7% 1.7% 3,146 3,049 3.2% 2.4% 0.8%
SPINE, SPORTS & OTHER
US 442 434 1.9% 1.9% - 1,658 1,696 (2.2)% (2.2)% -
Intl 312 300 4.2% (0.7)% 4.9% 1,193 1,230 (3.0)% (5.3)% 2.3%
WW 756 735 2.8% 0.8% 2.0% 2,852 2,926 (2.5)% (3.5)% 1.0%
See footnotes at end of schedule
% Change	% Change

-- 7 of 17 --

REPORTED SALES vs. PRIOR PERIOD ($MM) REPORTED SALES vs. PRIOR PERIOD ($MM)
FOURTH QUARTER TWELVE MONTHS
2025 2024 Reported Operational (1) Currency 2025 2024 Reported Operational (1) Currency
SURGERY
US 1,081	$ 1,038 4.2% 4.2% - 4,157	$ 4,003 3.9% 3.9% -
Intl 1,563 1,469 6.4% 3.4% 3.0% 5,980 5,842 2.4% 1.5% 0.9%
WW 2,644 2,507 5.5% 3.7% 1.8% 10,137 9,845 3.0% 2.5% 0.5%
ADVANCED
US 489 478 2.5% 2.5% - 1,900 1,838 3.4% 3.4% -
Intl 687 673 1.9% (0.8)% 2.7% 2,678 2,650 1.0% 0.1% 0.9%
WW 1,175 1,151 2.2% 0.6% 1.6% 4,577 4,488 2.0% 1.5% 0.5%
GENERAL
US 592 560 5.6% 5.6% - 2,258 2,165 4.3% 4.3% -
Intl 876 795 10.2% 6.9% 3.3% 3,302 3,192 3.4% 2.7% 0.7%
WW 1,468 1,357 8.3% 6.3% 2.0% 5,560 5,358 3.8% 3.3% 0.5%
VISION
US 531 509 4.3% 4.3% - 2,225 2,128 4.6% 4.6% -
Intl 889 794 11.9% 8.5% 3.4% 3,243 3,018 7.4% 5.9% 1.5%
WW 1,420 1,303 8.9% 6.8% 2.1% 5,468 5,146 6.3% 5.3% 1.0%
CONTACT LENSES / OTHER
US 417 396 5.3% 5.3% - 1,754 1,684 4.1% 4.1% -
Intl 592 541 9.3% 5.3% 4.0% 2,157 2,049 5.3% 3.2% 2.1%
WW 1,008 937 7.6% 5.3% 2.3% 3,910 3,733 4.8% 3.6% 1.2%
SURGICAL
US 113 113 0.6% 0.6% - 471 444 6.1% 6.1% -
Intl 297 252 17.7% 15.3% 2.4% 1,086 969 12.1% 11.6% 0.5%
WW 411 365 12.4% 10.8% 1.6% 1,558 1,413 10.2% 9.9% 0.3%
TOTAL MEDTECH
US 4,506 4,227 6.6% 6.6% - 17,408 16,332 6.6% 6.6% -
Intl 4,295 3,961 8.5% 4.9% 3.6% 16,384 15,525 5.5% 4.1% 1.4%
WW 8,801	$ 8,188 7.5% 5.8% 1.7% 33,792	$ 31,857 6.1% 5.4% 0.7%
* Percentage greater than 100% or not meaningful
(1) Operational growth excludes the effect of translational currency
(2) Unaudited
(3) Includes the sales of RYBREVANT and RYBREVANT + LAZCLUZE
(4) Reported as U.S. sales
(5) Acquired with Intra-Cellular Therapies on April 2, 2025
Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore,
may not recalculate precisely
% Change % Change

-- 8 of 17 --

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures)
Percent
Percent Percent Increase
Amount to Sales Amount to Sales (Decrease)
Sales to customers 24,564	$ 100.0 22,520	$ 100.0 9.1
Cost of products sold 7,968 32.4 7,128 31.6 11.8
Gross Profit 16,596 67.6 15,392 68.4 7.8
Selling, marketing and administrative expenses 6,753 27.5 6,453 28.6 4.6
Research and development expense 4,252 17.3 5,298 23.5 (19.7)
In-process research and development impairments 81 0.3 17 0.1
Interest (income) expense, net (23) (0.1) (144) (0.6)
Other (income) expense, net 483 2.0 (161) (0.7)
Restructuring 84 0.4 42 0.2
Earnings before provision for taxes on income 4,966 20.2 3,887 17.3 27.8
(Benefit from)/Provision for taxes on income (150) (0.6) 456 2.1 (132.9)
Net earnings 5,116	$ 20.8 3,431	$ 15.2 49.1
Net earnings per share (Diluted) 2.10	$ 1.41	$ 48.9
Average shares outstanding (Diluted) 2,439.0 2,427.1
Effective tax rate (3.0) % 11.7 %
Adjusted earnings before provision for taxes and net earnings (1)
Earnings before provision for taxes on income 7,046	$ 28.7 5,421	$ 24.1 30.0
Net earnings 6,009	$ 24.5 4,946	$ 22.0 21.5
Net earnings per share (Diluted) 2.46	$ 2.04	$ 20.6
Effective tax rate 14.7 % 8.8 %
(1) See Reconciliation of Non-GAAP Financial Measures.
FOURTH QUARTER
2025 2024

-- 9 of 17 --

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures)
Percent
Percent Percent Increase
Amount to Sales Amount to Sales (Decrease)
Sales to customers 94,193	$ 100.0 88,821	$ 100.0 6.0
Cost of products sold 30,256 32.1 27,471 30.9 10.1
Gross Profit 63,937 67.9 61,350 69.1 4.2
Selling, marketing and administrative expenses 23,676 25.1 22,869 25.7 3.5
Research and development expense 14,665 15.6 17,232 19.4 (14.9)
In-process research and development impairments 81 0.1 211 0.2
Interest (income) expense, net (85) (0.1) (577) (0.6)
Other (income) expense, net (7,209) (7.6) 4,694 5.3
Restructuring 228 0.2 234 0.3
Earnings before provision for taxes on income 32,581 34.6 16,687 18.8 95.2
Provision for taxes on income 5,777 6.1 2,621 3.0 120.4
Net earnings 26,804	$ 28.5 14,066	$ 15.8 90.6
Net earnings per share (Diluted) 11.03	$ 5.79	$ 90.5
Average shares outstanding (Diluted) 2,429.4 2,429.4
Effective tax rate 17.7 % 15.7 %
Adjusted earnings before provision for taxes and net earnings (1)
Earnings before provision for taxes on income 31,681	$ 33.6 28,979	$ 32.6 9.3
Net earnings 26,215	$ 27.8 24,242	$ 27.3 8.1
Net earnings per share (Diluted) 10.79	$ 9.98	$ 8.1
Effective tax rate 17.3 % 16.3 %
(1) See Reconciliation of Non-GAAP Financial Measures.
TWELVE MONTHS
2025 2024

-- 10 of 17 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Innovative Medicine MedTech Total
WW As Reported 10.0% 7.5% 9.1%
U.S. 7.9% 6.6% 7.5%
International 13.4% 8.5% 11.3%
WW Currency 2.1 1.7 2.0
U.S. - - -
International 5.5 3.6 4.7
WW Operational 7.9% 5.8% 7.1%
U.S. 7.9% 6.6% 7.5%
International 7.9% 4.9% 6.6%
Caplyta (1.7) (1.1)
U.S. (2.8) (1.9)
International 0.0 0.0
All Other Acquisitions and Divestitures (A&D) 0.0 0.1 0.1
U.S. 0.0 0.1 0.1
International 0.1 0.2 0.2
WW Adjusted Operational Ex A&D 6.2% 5.9% 6.1%
U.S. 5.1% 6.7% 5.7%
International 8.0% 5.1% 6.8%
Adjusted Operational Sales Growth
FOURTH QUARTER 2025 ACTUAL vs. 2024 ACTUAL
Segments
Note: Percentages are based on actual, non-rounded figures and may not sum

-- 11 of 17 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Innovative Medicine MedTech Total
WW As Reported 6.0% 6.1% 6.0%
U.S. 7.0% 6.6% 6.9%
International 4.6% 5.5% 5.0%
WW Currency 0.7 0.7 0.7
U.S. - - -
International 1.7 1.4 1.6
WW Operational 5.3% 5.4% 5.3%
U.S. 7.0% 6.6% 6.9%
International 2.9% 4.1% 3.4%
Shockwave (1.4) (0.5)
U.S. (2.1) (0.7)
International (0.5) (0.2)
Caplyta (1.2) (0.7)
U.S. (2.1) (1.4)
International 0.0 0.0
All Other Acquisitions and Divestitures (A&D) 0.0 0.3 0.1
U.S. 0.0 0.3 0.1
International 0.1 0.2 0.1
WW Adjusted Operational Ex A&D 4.1% 4.3% 4.2%
U.S. 4.9% 4.8% 4.9%
International 3.0% 3.8% 3.3%
Note: Percentages are based on actual, non-rounded figures and may not sum
Adjusted Operational Sales Growth
TWELVE MONTHS 2025 ACTUAL vs. 2024 ACTUAL
Segments

-- 12 of 17 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
(Dollars in Millions Except Per Share Data) 2025 2024 2025 2024
Net Earnings, after tax- as reported $5,116 $3,431 $26,804 $14,066
Pre-tax Adjustments
Litigation related 854 (16) (6,040) 5,450
Intangible Asset Amortization expense 1,186 1,171 4,621 4,526
Restructuring related 1 210 62 512 269
Acquisition, integration and divestiture related (190) 298 285 1,226
IPR&D impairments 81 17 81 211
(Gains)/losses on securities (100) (68) (427) 306
Orthopaedics Separation related 48 - 48 -
COVID-19 Vaccine related costs - 23 - 100
Medical Device Regulation - 47 - 204
Other (9) - 20 -
Tax Adjustments
Tax impact on special item adjustments 2 (445) (80) 381 (2,135)
Tax legislation and other tax related (742) 61 (70) 19
Adjusted Net Earnings, after tax $6,009 $4,946 $26,215 $24,242
Average shares outstanding (Diluted) 2,439.0 2,427.1 2,429.4 2,429.4
Adjusted net earnings per share (Diluted) $2.46 $2.04 $10.79 $9.98
Operational adjusted net earnings per share (Diluted) $2.35 $10.58
Notes:
1
2
Fourth Quarter Twelve Months Ended
In fiscal 2023, the company completed a prioritization of its research and development (R&D) investment within the Innovative Medicine segment to focus on the most promising medicines with the greatest
benefit to patients. This resulted in the exit of certain programs within therapeutic areas. The R&D program exits were primarily in infectious diseases and vaccines including the discontinuation of its respiratory
syncytial virus (RSV) adult vaccine program, hepatitis and HIV development. The restructuring expense of $102 million in fiscal 2024 included the termination of partnered and non-partnered program costs, asset
impairments and asset divestments. This program was completed in Q4 2024.
In fiscal 2023, the company initiated a restructuring program of its Orthopaedics franchise within the MedTech segment to streamline operations by exiting certain markets, product lines and distribution network
arrangements. The restructuring expense of $162 million in the fiscal fourth quarter of 2025 ($307 million Q4 2025 YTD) and $60 million in the fiscal fourth quarter of 2024 ($167 million Q4 2024 YTD) primarily
includes costs related to market and product exits. This program was substantially completed in Q4 2025.
In fiscal 2025, the company initiated a restructuring program of its Surgery franchise within the MedTech segment to simplify and focus operations by exiting certain non-strategic product lines and optimize
select sites across the network. The restructuring expense of $48 million in the fiscal fourth quarter of 2025 ($205 million Q4 2025 YTD) primarily includes costs related to asset impairments and market and
product exits. This program is expected to be substantially completed by the end of fiscal year 2026.
The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings.

-- 13 of 17 --

Innovative Medicine
Fourth Quarter
Dec. 28, 2025
GAAP
Intangible asset
amortization
Litigation
related
In-process
research and
development
impairments
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Orthopaedics
Separation
Related
Tax legislation
and other tax
related Other
Fourth Quarter
Dec. 28, 2025
Non-GAAP
Cost of products sold 3,976	$ (704) (11) 3,261
Selling, marketing and admin expenses 3,456 3,456
Research and development expense 3,466 3,466
Other segment items (193) 16 (11) (52) 101 4 (135)
Adjusted Income Before Tax by Segment 5,058 704 (16) 11 - 63 (101) - - (4) 5,715
MedTech
Fourth Quarter
Dec. 28, 2025
GAAP
Intangible asset
amortization
Litigation
related
In-process
research and
development
impairments
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Orthopaedics
Separation
Related
Tax legislation
and other tax
related Other
Fourth Quarter
Dec. 28, 2025
Non-GAAP
Cost of products sold 3,973	$ (482) (56) 3,435
Selling, marketing and admin expenses 3,035 3,035
Research and development expense 786 786
Other segment items 806 (818) (70) (154) 290 (1) (48) 5 10
Adjusted Income Before Tax by Segment 201 482 818 70 210 (290) 1 48 - (5) 1,535
Expenses not allocated to segments
Fourth Quarter
Dec. 28, 2025
GAAP
Intangible asset
amortization
Litigation
related
In-process
research and
development
impairments
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Orthopaedics
Separation
Related
Tax legislation
and other tax
related Other
Fourth Quarter
Dec. 28, 2025
Non-GAAP
Cost of products sold 19	$ 19
Selling, marketing and admin expenses 262 262
Research and development expense - -
Other segment items 12 (52) (37) (77)
Adjusted Income Before Tax by Segment (293) - 52 - - 37 - - - - (204)
Johnson & Johnson Consolidated
Fourth Quarter
Dec. 28, 2025
GAAP
Intangible asset
amortization
Litigation
related
In-process
research and
development
impairments
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Orthopaedics
Separation
Related
Tax legislation
and other tax
related Other
Fourth Quarter
Dec. 28, 2025
Non-GAAP
Cost of products sold 7,968	$ (1,186) (56) (11) 6,715
Selling, marketing and admin expenses 6,753 6,753
Research and development expense 4,252 4,252
Other (Income) / Expense 483 (854) (70) 201 100 (48) 9 (179)
In-process research and development impairments 81 (81) -
Interest (Income)/Expense (23) (23)
Restructuring 84 (84) -
Adjusted Income Before Tax 4,966 1,186 854 81 210 (190) (100) 48 - (9) 7,046
Provision for taxes on income (150) 226 32 18 35 149 (23) 11 742 (3) 1,037
Net Earnings 5,116	$ 960 822 63 175 (339) (77) 37 (742) (6) 6,009
Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
$ in Millions
Quarter to Date

-- 14 of 17 --

Innovative Medicine
Fourth Quarter
Dec. 29, 2024
GAAP
Intangible asset
amortization
Litigation
related
In-process
research and
development
impairments
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Medical Device
Regulation
COVID-19
Vaccine Related
Costs
Tax legislation
and other tax
related
Fourth Quarter
Dec. 29, 2024
Non-GAAP
Cost of products sold 3,514	$ (685) 2,829
Selling, marketing and admin expenses 3,312 3,312
Research and development expense 3,698 (6) 3,692
Other segment items (201) 41 (17) (2) (12) 50 (17) (158)
Adjusted Income Before Tax by Segment 4,009 685 (41) 17 2 12 (50) - 23 - 4,657
MedTech
Fourth Quarter
Dec. 29, 2024
GAAP
Intangible asset
amortization
Litigation
related
In-process
research and
development
impairments
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Medical Device
Regulation
COVID-19
Vaccine Related
Costs
Tax legislation
and other tax
related
Fourth Quarter
Dec. 29, 2024
Non-GAAP
Cost of products sold 3,596	$ (477) (20) (153) (18) 2,928
Selling, marketing and admin expenses 2,836 (4) 2,832
Research and development expense 1,600 (25) 1,575
Other segment items 84 (9) 29 (40) (115) 18 (33)
Adjusted Income Before Tax by Segment 72 486 (29) - 60 268 (18) 47 - - 886
Expenses not allocated to segments
Fourth Quarter
Dec. 29, 2024
GAAP
Intangible asset
amortization
Litigation
related
In-process
research and
development
impairments
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Medical Device
Regulation
COVID-19
Vaccine Related
Costs
Tax legislation
and other tax
related
Fourth Quarter
Dec. 29, 2024
Non-GAAP
Cost of products sold 18	$ 18
Selling, marketing and admin expenses 305 305
Research and development expense - -
Other segment items (129) (54) (18) (201)
Adjusted Income Before Tax by Segment (194) - 54 - - 18 - - - - (122)
Johnson & Johnson Consolidated
Fourth Quarter
Dec. 29, 2024
GAAP
Intangible asset
amortization
Litigation
related
In-process
research and
development
impairments
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Medical Device
Regulation
COVID-19
Vaccine Related
Costs
Tax legislation
and other tax
related
Fourth Quarter
Dec. 29, 2024
Non-GAAP
Cost of products sold 7,128	$ (1,162) (20) (153) (18) 5,775
Selling, marketing and admin expenses 6,453 (4) 6,449
Research and development expense 5,298 (25) (6) 5,267
Other (Income) / Expense (161) (9) 16 (145) 68 (17) (248)
In-process research and development impairments 17 (17) -
Interest (Income)/Expense (144) (144)
Restructuring 42 (42) -
Adjusted Income Before Tax 3,887 1,171 (16) 17 62 298 (68) 47 23 - 5,421
Provision for taxes on income 456 171 (158) 4 3 80 (34) 9 5 (61) 475
Net Earnings 3,431	$ 1,000 142 13 59 218 (34) 38 18 61 4,946
Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
$ in Millions
Quarter to Date

-- 15 of 17 --

Year to Date
Innovative Medicine
Twelve Months
Dec. 28, 2025
GAAP
Intangible asset
amortization
Litigation
related
In-process
research and
development
impairments
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Orthopaedics
Separation
Related
Tax legislation
and other tax
related Other
Twelve Months
Dec. 28, 2025
Non-GAAP
Cost of products sold 15,646	$ (2,706) (35) 12,905
Selling, marketing and admin expenses 11,375 11,375
Research and development expense 11,827 11,827
Other segment items (713) 90 (11) (327) 265 (10) (706)
Adjusted Income Before Tax by Segment 22,266 2,706 (90) 11 - 362 (265) - - 10 25,000
MedTech
Twelve Months
Dec. 28, 2025
GAAP
Intangible asset
amortization
Litigation
related
In-process
research and
development
impairments
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Orthopaedics
Separation
Related
Tax legislation
and other tax
related Other
Twelve Months
Dec. 28, 2025
Non-GAAP
Cost of products sold 14,549	$ (1,915) (91) (52) 12,491
Selling, marketing and admin expenses 11,354 11,354
Research and development expense 2,838 37 2,875
Other segment items 938 (896) (70) (421) 135 162 (48) (10) (210)
Adjusted Income Before Tax by Segment 4,113 1,915 896 70 512 (120) (162) 48 - 10 7,282
Expenses not allocated to segments
Twelve Months
Dec. 28, 2025
GAAP
Intangible asset
amortization
Litigation
related
In-process
research and
development
impairments
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Orthopaedics
Separation
Related
Tax legislation
and other tax
related Other
Twelve Months
Dec. 28, 2025
Non-GAAP
Cost of products sold 61	$ 61
Selling, marketing and admin expenses 947 947
Research and development expense - -
Other segment items (7,210) 6,846 (43) (407)
Adjusted Income Before Tax by Segment 6,202 - (6,846) - - 43 - - - - (601)
Johnson & Johnson Consolidated
Twelve Months
Dec. 28, 2025
GAAP
Intangible asset
amortization
Litigation
related
In-process
research and
development
impairments
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Orthopaedics
Separation
Related
Tax legislation
and other tax
related Other
Twelve Months
Dec. 28, 2025
Non-GAAP
Cost of products sold 30,256	$ (4,621) (91) (87) 25,457
Selling, marketing and admin expenses 23,676 23,676
Research and development expense 14,665 37 14,702
Other (Income) / Expense (7,209) 6,040 (193) (235) 427 (48) (20) (1,238)
In-process research and development impairments 81 (81) -
Interest (Income)/Expense (85) (85)
Restructuring 228 (228) -
Adjusted Income Before Tax 32,581 4,621 (6,040) 81 512 285 (427) 48 - 20 31,681
Provision for taxes on income 5,777 829 (1,509) 18 93 267 (96) 11 70 6 5,466
Net Earnings 26,804	$ 3,792 (4,531) 63 419 18 (331) 37 (70) 14 26,215
Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
$ in Millions

-- 16 of 17 --

Innovative Medicine
Twelve Months
Dec. 29, 2024
GAAP
Intangible asset
amortization
Litigation
related
In-process
research and
development
impairments
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Medical Device
Regulation
COVID-19
Vaccine Related
Costs
Tax legislation
and other tax
related
Twelve Months
Dec. 29, 2024
Non-GAAP
Cost of products sold 14,036	$ (2,772) (8) 11,256
Selling, marketing and admin expenses 10,906 10,906
Research and development expense 13,529 (25) 13,504
Other segment items (426) (358) (211) (102) (66) 76 (67) (1,154)
Adjusted Income Before Tax by Segment 18,919 2,772 358 211 102 66 (76) - 100 - 22,452
MedTech
Twelve Months
Dec. 29, 2024
GAAP
Intangible asset
amortization
Litigation
related
In-process
research and
development
impairments
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Medical Device
Regulation
COVID-19
Vaccine Related
Costs
Tax legislation
and other tax
related
Twelve Months
Dec. 29, 2024
Non-GAAP
Cost of products sold 13,345	$ (1,745) (35) (359) (84) 11,122
Selling, marketing and admin expenses 10,812 (16) 10,796
Research and development expense 3,703 (69) (104) 3,530
Other segment items 257 (9) 14 (132) (587) (30) (487)
Adjusted Income Before Tax by Segment 3,740 1,754 (14) - 167 1,015 30 204 - - 6,896
Expenses not allocated to segments
Twelve Months
Dec. 29, 2024
GAAP
Intangible asset
amortization
Litigation
related
In-process
research and
development
impairments
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Medical Device
Regulation
COVID-19
Vaccine Related
Costs
Tax legislation
and other tax
related
Twelve Months
Dec. 29, 2024
Non-GAAP
Cost of products sold 90	$ 90
Selling, marketing and admin expenses 1,151 1,151
Research and development expense - -
Other segment items 4,731 (5,106) (145) (352) (872)
Adjusted Income Before Tax by Segment (5,972) - 5,106 - - 145 352 - - - (369)
Johnson & Johnson Consolidated
Twelve Months
Dec. 29, 2024
GAAP
Intangible asset
amortization
Litigation
related
In-process
research and
development
impairments
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Medical Device
Regulation
COVID-19
Vaccine Related
Costs
Tax legislation
and other tax
related
Twelve Months
Dec. 29, 2024
Non-GAAP
Cost of products sold 27,471	$ (4,517) (35) (359) (84) (8) 22,468
Selling, marketing and admin expenses 22,869 (16) 22,853
Research and development expense 17,232 (69) (104) (25) 17,034
Other (Income) / Expense 4,694 (9) (5,450) (798) (306) (67) (1,936)
In-process research and development impairments 211 (211) -
Interest (Income)/Expense (577) (577)
Restructuring 234 (234) -
Adjusted Income Before Tax 16,687 4,526 5,450 211 269 1,226 306 204 100 - 28,979
Provision for taxes on income 2,621 644 1,066 47 45 302 (29) 38 22 (19) 4,737
Net Earnings 14,066	$ 3,882 4,384 164 224 924 335 166 78 19 24,242
Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
$ in Millions
Year to Date

-- 17 of 17 --